MRI and blood tests study in soft tissue sarcoma
Part of Cancer clinical trials.
This Phase 2 trial looks at how two test approaches (an MRI-based scan and blood tests) work in people with a larger, grade 2 or 3 soft tissue sarcoma. It may help researchers learn better ways to measure the disease and guide care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You can understand the study and agree to sign an informed consent form.
- You have soft tissue sarcoma that is grade 2 or grade 3.
- Your tumor is larger than 5 centimeters at its biggest point.
- If your care requires an MRI, you must not have a reason you can’t safely get an MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks if a blood test can detect DNA from soft tissue sarcomas. The goal is to see if circulating tumor DNA can help doctors monitor the disease and plan treatment.
This study looks at how people with soft tissue sarcoma take part in clinical trials. By joining, you help researchers learn more about trial participation, which may lead to better access to new treatments for others.
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
This study is for people who have been diagnosed with bone or soft tissue sarcoma confirmed by a tissue test. It may help researchers understand sarcoma better, but you must be able to understand and consent to take part.
This trial tests a personalized (“adaptive”) radiation plan before surgery for high-grade soft-tissue sarcoma that can be removed. It may help shrink the tumor and improve how well surgery can treat the cancer.
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
Hear when a new Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.